Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences RNAi & miRNA

Christopher Cheng's Biography



Christopher Cheng, Postdoctoral Fellow, Yale University

Christopher Cheng received his Ph.D. in Molecular Biophysics & Biochemistry from Yale University in 2011 researching nanoscale delivery systems for cancer-targeted gene therapy. Specifically, he engineered surface-enhanced polymer nanoparticles to deliver agents (e.g. microRNA inhibitors, siRNA, and splicing blockers) that regulate the expression of genes that are involved in the onset and progression of cancer. Currently working with Frank Slack, Don Engelman, and Mark Saltzman at Yale, he is interested in understanding the molecular basis for how certain cancers can become addicted to the overexpression of oncogenic microRNAs, or oncomiRs. He is also continuing the development of novel technologies to antagonize microRNAs as therapeutic targets.

Christopher Cheng Image

Surface-Enhanced Polymer Nanoparticles for Inhibition of Oncogenic MicroRNAs

Thursday, 19 April 2012 at 14:45

Add to Calendar ▼2012-04-19 14:45:002012-04-19 15:45:00Europe/LondonSurface-Enhanced Polymer Nanoparticles for Inhibition of Oncogenic MicroRNAsSELECTBIOenquiries@selectbiosciences.com

Cancers can become addicted to oncogenic microRNAs. I will detail the development of a nanotherapeutic system that elicits microRNA inhibition in solid tumors. Blocking miR-155 in a model of miR-155-addicted lymphoma inhibited tumor growth; introducing a new platform for microRNA therapeutics.


Add to Calendar ▼2012-04-19 00:00:002012-04-20 00:00:00Europe/LondonRNAi and miRNASELECTBIOenquiries@selectbiosciences.com